Perspective Therapeutics, Inc.
CATX
$3.00
$0.072.39%
AMEX
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 76.74% | -79.43% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 76.74% | -79.43% | |||
| Cost of Revenue | -35.09% | 61.88% | |||
| Gross Profit | 35.23% | -63.34% | |||
| SG&A Expenses | 0.49% | -10.09% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -28.89% | 42.06% | |||
| Operating Income | 29.00% | -42.97% | |||
| Income Before Tax | 31.59% | -47.42% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 30.14% | -44.36% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 30.14% | -44.36% | |||
| EBIT | 29.00% | -42.97% | |||
| EBITDA | 30.06% | -43.35% | |||
| EPS Basic | 49.87% | -44.29% | |||
| Normalized Basic EPS | 50.92% | -47.32% | |||
| EPS Diluted | 49.87% | -44.29% | |||
| Normalized Diluted EPS | 50.92% | -47.32% | |||
| Average Basic Shares Outstanding | 39.36% | 0.06% | |||
| Average Diluted Shares Outstanding | 39.36% | 0.06% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||